KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $44.3 million.

  • Nektar Therapeutics' Cash & Equivalents rose 36.28% to $41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.0 million, marking a year-over-year increase of 36.28%. This contributed to the annual value of $44.3 million for FY2024, which is 25.44% up from last year.
  • Per Nektar Therapeutics' latest filing, its Cash & Equivalents stood at $44.3 million for FY2024, which was up 25.44% from $35.3 million recorded in FY2023.
  • Nektar Therapeutics' 5-year Cash & Equivalents high stood at $199.0 million for FY2020, and its period low was $25.2 million during FY2021.
  • Its 3-year average for Cash & Equivalents is $55.9 million, with a median of $44.3 million in 2024.
  • As far as peak fluctuations go, Nektar Therapeutics' Cash & Equivalents plummeted by 87.32% in 2021, and later soared by 249.86% in 2022.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Cash & Equivalents stood at $199.0 million in 2020, then slumped by 87.32% to $25.2 million in 2021, then soared by 249.86% to $88.2 million in 2022, then crashed by 60.02% to $35.3 million in 2023, then rose by 25.44% to $44.3 million in 2024.